Overview
Invivyd Q3 2025 revenue grows 41% yr/yr to $13.1 mln
Net loss for Q3 2025 beats analyst estimates
Adjusted loss per share for Q3 2025 beats consensus
Company receives FDA clearance for VYD2311 clinical program
Outlook
Invivyd expects to begin pivotal trials for VYD2311 by year-end 2025
Top-line data for VYD2311 trials anticipated mid-2026
Company plans pipeline expansion beyond COVID to include RSV and measles
Result Drivers
PEMGARDA SALES - Growth in PEMGARDA sales among healthcare providers treating immunocompromised patients contributed to revenue increase
FDA CLEARANCE - FDA clearance for VYD2311 clinical program positions Invivyd for future growth in COVID-19 prevention
CASH POSITION - Cash reserves strengthened by public offering and ATM facility usage, supporting future investments
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $13.13 mln | ||
Q3 EPS | Beat | -$0.06 | -$0.08 (3 Analysts) |
Q3 Net Income | Beat | -$10.47 mln | -$12.44 mln (2 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Invivyd Inc is $10.00, about 84.8% above its November 5 closing price of $1.52
Press Release: ID:nGNX3zFg4p
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)